Expertise in
13
conditions

Dr. Sarah J. Sinclair

Hematology
Office
33 Whiting Hill Rd Ste 21, 
Brewer, ME 
Offers Telehealth
Expertise in
13
conditions
Office
33 Whiting Hill Rd Ste 21, 
Brewer, ME 

Overview

Sarah Sinclair is a Hematologist practicing medicine in Brewer, Maine.

Dr. Sinclair is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 73 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in ME

Hospital Affiliations

Houlton Regional Hospital
Northern Light Maine Coast Hospital
Northern Light Blue Hill Memorial Hospital
Northern Light Eastern Maine Medical Center
Millinocket Regional Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Office
33 Whiting Hill Rd Ste 21, Brewer, ME 04412

Additional Areas of Focus

Dr. Sinclair has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

72 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

12 Total Publications

TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.
Journal: ESMO open
Published: April 10, 2026
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Office

43 Whiting Hill Rd Ste 300, 
Brewer, ME 
 (0.1 miles away)
207-973-7478
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Astrid Andreescu is a Hematologist practicing medicine in Brewer, Maine. Dr. Andreescu is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Multiple Myeloma, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Brewer-Northern Light Cancer Care

33 Whiting Hill Rd, 
Brewer, ME 
 (1.0 miles away)
207-973-7478
Languages Spoken:
English
See accepted insurances

Philip Brooks is a Hematologist practicing medicine in Brewer, Maine. Dr. Brooks is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Adult T-Cell Leukemia, Chronic T-Cell Leukemia (CTCL), and Muscle Invasive Bladder Cancer.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Mainehealth Cancer Care-Belfast

116 Northport Ave Ste 112, 
Belfast, ME 
 (26.7 miles away)
207-505-4163
Languages Spoken:
English
See accepted insurances

Sigrid Berg is a Hematologist practicing medicine in Belfast, Maine. Dr. Berg is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Gastric Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Sarah J. Sinclair

How do I make an appointment with Dr. Sarah J. Sinclair?

You can book an appointment with Dr. Sarah J. Sinclair by calling their office at 207-973-7807. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sarah J. Sinclair a top-rated expert for Adult Immune Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sarah J. Sinclair is classified as an Distinguished expert for Adult Immune Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sarah J. Sinclair specialize in?

While Dr. Sarah J. Sinclair is a Hematology, they have specific expertise in Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sarah J. Sinclair participate in research or clinical trials?

Yes. Dr. Sarah J. Sinclair has published 12 articles and abstracts on conditions like Adult Immune Thrombocytopenia. You can view a list of Dr. Sarah J. Sinclair's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sarah J. Sinclair accept my insurance?

Dr. Sarah J. Sinclair accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 207-973-7807 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sinclair's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile